INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 178 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $2,226,000 | -1.0% | 15,600 | -10.9% | 0.04% | -5.4% |
| Q1 2016 | $2,248,000 | -14.0% | 17,500 | 0.0% | 0.04% | -9.8% |
| Q4 2015 | $2,614,000 | -10.0% | 17,500 | 0.0% | 0.04% | -18.0% |
| Q3 2015 | $2,903,000 | -1.4% | 17,500 | +43.4% | 0.05% | +16.3% |
| Q2 2015 | $2,945,000 | -0.5% | 12,200 | +16.2% | 0.04% | -2.3% |
| Q1 2015 | $2,961,000 | +58.2% | 10,500 | -12.5% | 0.04% | +57.1% |
| Q4 2014 | $1,872,000 | -34.1% | 12,000 | 0.0% | 0.03% | -31.7% |
| Q3 2014 | $2,840,000 | +100.0% | 12,000 | +100.0% | 0.04% | +86.4% |
| Q2 2014 | $1,420,000 | – | 6,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |